Glucotrack Inc

This advisory Say‑on‑Pay proposal asks shareholders to approve, on a non‑binding basis, the Company’s 2025 named executive officer (NEO) compensation as disclosed in the proxy. Management is seeking this advisory approval to provide stockholders with an opportunity to express views on pay philosophy and total executive compensation, and to continue periodic three‑year Say‑on‑Pay votes in accordance with Dodd‑Frank/SEC rules. The board frames the compensation program as pay‑for‑performance and as designed to attract and retain experienced executives critical to advancing clinical and commercial plans; it also notes that compensation may include cash salary, bonuses tied to corporate and individual milestones, and equity incentives. Although non‑binding, the board and compensation committee state they consider the outcome when setting future pay and previously relied on prior Say‑on‑Pay results in their deliberations. The proposal does not target specific awards but the overall disclosure (including summary compensation tables and equity grants) and is a governance signal for alignment with shareholders. Risks include potential dissatisfaction if realized pay is perceived as misaligned with performance or dilution from equity awards; conversely, strong support would validate management’s pay approach. Given the company’s small reporting company status, disclosure is limited versus larger peers which may complicate direct comparisons. The board’s recommendation of FOR is justified by its view that current programs support retention and incentivize achievement of strategic milestones while aligning long‑term interests with stockholders. In evaluating the merits, an analyst should weigh the non‑binding nature of the vote, the specific incentive structures described in the proxy (e.g., milestone bonuses and option grants), historical Say‑on‑Pay outcomes and how the company incorporates shareholder feedback into future compensation decisions.

This proposal seeks shareholder authorization to amend the Certificate of Incorporation to permit management to implement one or more reverse stock splits at an aggregate ratio of up to 1‑for‑30, exercisable at management’s discretion within one year. Management frames the reverse split primarily as a tool to regain or maintain compliance with Nasdaq’s $1.00 minimum bid price requirement and to avoid potential delisting, while also citing potential secondary benefits such as increased marketability, eligibility for a broader set of institutional investors, and potentially greater analyst and broker interest. The proposal grants management flexibility to choose the specific ratio(s) (up to 1:30) and to abandon the action if conditions change, which is intended to allow responsiveness to market conditions but also concentrates significant execution discretion in management. Implementation would reduce outstanding share count proportionately, adjust derivative securities and equity plan share counts and typically round fractional interests up to whole shares per the company’s stated treatment. Risks include the possibility that the market price may not increase proportionately, reduced liquidity due to fewer shares outstanding, and potentially larger percentage declines in market capitalization if post‑split shares trade down; shareholders could also experience increased volatility. The board justifies the measure as preferable to delisting, noting the relatively modest post‑split outstanding share count at the maximum ratio and the administrative mechanics (CUSIP change, Nasdaq “D” suffix). From a governance perspective, the DGCL change reduces the vote threshold to a majority of votes cast and treats the matter as routine for broker voting purposes; this increases the likelihood management can implement a split quickly if approved. An analyst evaluating this proposal should weigh the immediate listing compliance rationale and management’s retained discretion against the historical mixed outcomes of reverse splits and the potential for adverse liquidity and valuation effects.

This proposal requests shareholder approval to permit management, for a six‑month period following approval, to effect one warrant inducement transaction consisting of (i) a repricing of then‑outstanding warrants to no lower than 70% of the Minimum Price and (ii) issuance of inducement warrants (up to 200% of the then‑issuable shares) in connection with a contemporaneous cash exercise of repriced warrants. Management is seeking this approval to comply with Nasdaq Listing Rule 5635(d), which requires shareholder approval for issuances of shares in transactions (other than public offerings) at prices below the Minimum Price when such issuance could exceed 20% of outstanding shares; by obtaining pre‑approval, the board preserves flexibility to negotiate a transaction that would bring in cash proceeds while avoiding a separate shareholder vote later. The company explains the inducement as a way to incentivize the existing warrant holder(s) to accept a repricing and immediately convert warrants into cash proceeds, which could materially improve the company’s liquidity and working capital position. The primary countervailing concern is dilution: the proxy acknowledges the potential issuance of up to an aggregate maximum (based on current levels) of approximately 6.2 million shares if repriced and inducement warrants are issued, which would be highly dilutive to existing holders and could depress book value and EPS. The approval is non‑specific as to the exact reduced exercise price (other than a floor of 70% of Minimum Price) and number of inducement warrants, leaving substantial negotiating latitude to management and counterparties. If stockholder approval is withheld, the company could be unable to obtain the potential cash proceeds from warrant exercises under amended terms, which management claims could impair its ability to fund operations. Analysts should evaluate the likelihood that inducement will produce immediate cash inflows, the dilution trade‑off, potential effects on control (ownership caps in the warrants), and alternative financing options before assessing the net benefit to shareholders.